Gleevec (Imatinib)
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Gleevec (Imatinib) |
| FDA Approval | Yes (for chronic myelogenous leukemia and other cancers, not specifically approved for gliomas) |
| Used for | Investigational use in gliomas, specifically targeting overexpression of platelet-derived growth factor receptor (PDGFR) |
| Clinical Trial Phase | Exploratory/Investigational (Specific phase for gliomas not provided) |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Varies; for leukemia treatment includes fluid retention, nausea, muscle cramps, rashes, and fatigue. Brain tumor studies may have different profiles due to combination treatments and patient population. |
| OS without | Not specified |
| OS with | Not applicable; studies focusing on PFS-6 as a primary endpoint |
| PFS without | Not specified |
| PFS with | PFS-6 value was 53% in a restricted patient population with overexpression of PDGFR |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Gleevec, known for its role in leukemia treatment, has shown potential in inhibiting glioma growth due to its targeting of PDGF. Its effectiveness in brain tumors has been limited, possibly due to issues crossing the blood-brain barrier and various resistance mechanisms. Its use has been explored in patients with recurrent tumors and PDGFR overexpression, showing some promise in early research.
From Ben Williams Book: Not specified
Loading comments...
